PMN
ProMIS Neurosciences Inc.
$9.74
+0.36%
$87.1M
No data for this timeframe.
Vol
Market Cap$87.1M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders3 funds
Inst. Value$9.6K
Insider Activity5B / 0S
Insider Net $$8.6M
SEC Reports4
Press Releases1
Recent Activity
May 28, 2026
Press
ProMIS Neurosciences announced participation in five June 2026 investor conferences and reiterated its timeline for the
Impact 3/10
May 28, 2026
announcement
ProMIS Neurosciences to Participate in Upcoming Conferences in June
<p align="left">CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasd
May 20, 2026
Insider
Kaplan Johanne sold 50,000 shares
Chief Development Officer @ $0.00 ($0.00)
May 20, 2026
Insider
Milbury Max A. sold 18,167 shares
Principal Accounting Officer @ $0.00 ($0.00)
May 20, 2026
Insider
Alex Slanix Paul sold 5,500 shares
Director @ $0.00 ($0.00)
May 12, 2026
SEC
ProMIS Neurosciences reported Q1 2026 financial results, highlighting a net loss of $8.2 million (vs $7.3 million in Q1
8-K — Impact 4/10
Apr 3, 2026
SEC
ProMIS Neurosciences' S-3 shelf registration has become effective, allowing the company to raise up to $200 million thro
EFFECT — Impact 7/10
Mar 25, 2026
SEC
ProMIS Neurosciences filed an S-3 shelf registration allowing it to raise up to $200 million through various securities,
S-3 — Impact 6/10
Price Targets
$35.01
+259.2% upside
Strong Buy
Current $9.75
Low $17.87
Median $34.49
High $48.74
5 analysts
$17.87
$48.74
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 6, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-2.19 ▼ -43.0% | $-2.88 — $-1.83 | 78% YoY | 4 |
| Next Q | $-2.17 ▼ -45.5% | $-3.32 — $-1.54 | 74% YoY | 4 |
| Current FY | $-6.31 ▼ -4.3% | $-8.25 — $-2.83 | 80% YoY | 4 |
| Next FY | $-5.38 ▲ +19.7% | $-7.70 — $-1.64 | 15% YoY | 4 |
Latest Reports
NEUTRAL
Press
3/10
ProMIS Neurosciences announced participation in five June 2026 investor conferences and reiterated its timeline for the
May 28, 2026
NEUTRAL
8-K
4/10
ProMIS Neurosciences reported Q1 2026 financial results, highlighting a net loss of $8.2 million (vs $7.3 million in Q1
May 12, 2026
BEARISH
EFFECT
7/10
ProMIS Neurosciences' S-3 shelf registration has become effective, allowing the company to raise up to $200 million thro
Apr 3, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| TWO SIGMA INVESTMENTS, LP | $7.8K | — |
| UBS Group AG | $1.1K | — |
| BANK OF AMERICA CORP | $708.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 20, 2026 | Kaplan Johanne | A | $0.00 |
| May 20, 2026 | Milbury Max | A | $0.00 |
| May 20, 2026 | Alex Slanix | A | $0.00 |
| May 20, 2026 | Mandel-Brehm Josh | A | $0.00 |
| May 20, 2026 | Cashman Neil | A | $0.00 |
3 institutional holders with $9.6K total value (22,600 shares) as of 2025-Q3. Top holders: TWO, UBS, BANK.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | 18,428 | $7.8K | 81.5% | — |
| 2 | UBS Group AG | 2,506 | $1.1K | 11.1% | — |
| 3 | BANK OF AMERICA CORP /DE/ | 1,666 | $708.00 | 7.4% | — |
11 unique insiders with 5 transactions. Net insider value: $8.6M ($8.6M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 20, 2026 | Kaplan Johanne | Chief Development Officer | A | 50,000 | $0.00 | $0.00 |
| May 20, 2026 | Milbury Max A. | Principal Accounting Officer | A | 18,167 | $0.00 | $0.00 |
| May 20, 2026 | Alex Slanix Paul | Director | A | 5,500 | $0.00 | $0.00 |
| May 20, 2026 | Mandel-Brehm Josh | Director | A | 5,500 | $0.00 | $0.00 |
| May 20, 2026 | Cashman Neil | Chief Scientific Officer | A | 50,000 | $0.00 | $0.00 |
| May 20, 2026 | Shafmaster Madge K. | Director | A | 5,500 | $0.00 | $0.00 |
| May 20, 2026 | Warma Neil K | Chief Executive Officer | A | 160,000 | $0.00 | $0.00 |
| May 20, 2026 | Williams Eugene | Director | A | 5,500 | $0.00 | $0.00 |
| May 20, 2026 | WYMAN WILLIAM W | Director | A | 5,500 | $0.00 | $0.00 |
| Apr 22, 2026 | Kirwin Patrick D. | Director | BUY | 4,000 | $11.33 | $45.3K |
| Mar 5, 2026 | Williams Eugene | Director | BUY | 2,000 | $24.40 | $48.8K |
| Feb 19, 2026 | Kaplan Johanne | Chief Development Officer | BUY | 1,629 | $15.35 | $25.0K |
| Feb 3, 2026 | Kirwin Patrick D. | Director | A | 3,050 | $12.13 | $37.0K |
| Feb 3, 2026 | Kirwin Patrick D. | Director | A | 3,050 | $0.00 | $0.00 |
| Feb 3, 2026 | Warma Neil K | Chief Executive Officer | A | 6,183 | $12.13 | $75.0K |
| Feb 3, 2026 | Warma Neil K | Chief Executive Officer | A | 6,183 | $0.00 | $0.00 |
| Feb 3, 2026 | Kaplan Johanne | Chief Development Officer | A | 2,060 | $12.13 | $25.0K |
| Feb 3, 2026 | Kaplan Johanne | Chief Development Officer | A | 2,060 | $0.00 | $0.00 |
| Feb 3, 2026 | ABG Management Ltd. | Director | BUY | 700,741 | $12.13 | $8.5M |
| Feb 3, 2026 | ABG Management Ltd. | Director | BUY | 700,741 | $0.00 | $0.00 |
| Feb 3, 2026 | Milbury Max A. | A | 6,595 | $12.13 | $80.0K | |
| Feb 3, 2026 | Milbury Max A. | A | 6,595 | $0.00 | $0.00 | |
| Feb 3, 2026 | Cashman Neil | Chief Scientific Officer | A | 4,122 | $12.13 | $50.0K |
| Feb 3, 2026 | Cashman Neil | Chief Scientific Officer | A | 4,122 | $0.00 | $0.00 |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 0 mixed, 1 neutral. Avg impact: 6.0/10.
NEUTRAL
8-K
4/10
ProMIS Neurosciences reported Q1 2026 financial results, highlighting a net loss of $8.2 million (vs
May 12, 2026
BEARISH
EFFECT
7/10
ProMIS Neurosciences' S-3 shelf registration has become effective, allowing the company to raise up
Apr 3, 2026
BEARISH
S-3
6/10
ProMIS Neurosciences filed an S-3 shelf registration allowing it to raise up to $200 million through
Mar 25, 2026
BEARISH
S-3
7/10
ProMIS Neurosciences filed an S-3 shelf registration to register 13,830,592 common shares for resale
Mar 18, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$35.01 mean target
+259.2% upside
Strong Buy (3.00)
$17.87 Low
$48.74 High
| Metric | Value |
|---|---|
| Current Price | $9.75 |
| Target Low | $17.87 |
| Target Mean | $35.01 |
| Target Median | $34.49 |
| Target High | $48.74 |
| # Analysts | 5 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-2.19 | $-2.88 | $-1.83 | 78.1% | -43.0% | 0↑ 1↓ | $0.0B | 0.0% | 4 |
| Next Q 2026-09-30 |
$-2.17 | $-3.32 | $-1.54 | 74.2% | -45.5% | 0↑ 1↓ | $0.0B | 0.0% | 4 |
| Current FY 2026-12-31 |
$-6.31 | $-8.25 | $-2.83 | 79.7% | -4.3% | 0↑ 1↓ | $0.0B | 0.0% | 4 |
| Next FY 2027-12-31 |
$-5.38 | $-7.70 | $-1.64 | 14.7% | +19.7% | 1↑ 1↓ | $0.0B | 0.0% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-2.190 | |
| 7d ago | $-1.532 | -0.658 |
| 30d ago | $-1.532 | -0.658 |
| 60d ago | $-2.421 | +0.231 |
| 90d ago | $-2.421 | +0.231 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 6, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 28, 2026
announcement
ProMIS Neurosciences to Participate in Upcoming Conferences in June
<p align="left">CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company d
May 12, 2026
announcement
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
<p align="justify"><b>Cambridge, Massachusetts, May 12, 2026 (GLOBE NEWSWIRE) -- </b>ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biote
May 11, 2026
earnings_calendar
PMN Q1 2026 Earnings Scheduled — 2026-05-11
Mar 30, 2026
earnings_calendar
PMN Q4 2025 Earnings After Market Close — 2026-03-30
Feb 2, 2026
short_interest
FTD: PMN — 110,785 shares ($1.6M) failed to deliver
Settlement: 20260202, Price: $14.16, FTD Value: $1,568,715.6, PROMIS NEUROSCIENCES INC COM N